In a groundbreaking medical development that could save thousands of lives, British researchers have unveiled a new breath test capable of detecting pancreatic cancer in its early stages — a disease known as one of the deadliest and hardest to diagnose. Experts describe this step as the most significant breakthrough in 50 years, potentially ushering in a new era of early detection and effective treatment.
According to PA Media, a new clinical trial is currently underway in the United Kingdom to assess the effectiveness of the world’s first breath test designed to detect pancreatic cancer — one of the most elusive and aggressive cancers to diagnose early.
The Pancreatic Cancer UK organization, which is funding the study, said the launch of this trial marks “the most important step toward a life-saving breakthrough in half a century,” emphasizing that early detection remains the key to improving survival rates.
Pancreatic cancer is often called the “silent killer”, as its symptoms — including back pain, indigestion, and loss of appetite — are vague and easily mistaken for less serious conditions. As a result, the disease is frequently diagnosed only after it has spread to other parts of the body.
A recent review in England and Wales found that around 62% of patients in England and 65% in Wales are diagnosed at stage four, when treatment options are extremely limited.
Statistics also show alarmingly low survival rates, with only 22% of patients in England and 21% in Wales surviving beyond 30 days after diagnosis — a grim reality that researchers hope to change through earlier detection.
Scientists now hope the new breath test will prove capable of identifying biochemical markers of the disease at its earliest stage, offering a simple, non-invasive diagnostic tool that could transform patient outcomes and save countless lives worldwide.
